Entry Detail

General Information

Database ID: LDA0005342
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Yes

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:PCBP2-OT1
Full Name:PCBP2 overlapping transcript 1
Category:LncRNA
Species:Homo sapiens
Synonyms:TUC.338|TUC338|uc.338
Chromosome:12
Strand:+
Coordinate:
Start Site(bp):53464468End Site(bp):53465057
External Links:
Ensembl ID:ENSG00000282977
Ensembl Transcript ID:N/A
Entrez Gene:102157401.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:10   
More Information
Causal Disease Number:10
Network:
Top Causal Diseases:
Esophageal Neoplasms  (Score: 0.731059)
Urinary Bladder Neoplasms  (Score: 0.731059)
prostate carcinoma  (Score: 0.731059)
Nasopharyngeal Neoplasms  (Score: 0.731059)
Lymphoma, Large B-Cell, Diffuse  (Score: 0.731059)
Esophageal Neoplasms  (Score: 0.731059)
Urinary Bladder Neoplasms  (Score: 0.731059)
prostate carcinoma  (Score: 0.731059)
Nasopharyngeal Neoplasms  (Score: 0.731059)
Lymphoma, Large B-Cell, Diffuse  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:0050745D016403
Disease Name:diffuse large B-cell lymphomaLymphoma, Large B-Cell, Diffuse
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A B-cell lymphoma that is a cancer of B cells presenting as an aggressive tumour which can arise in virtually any part of the body.Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Alias:Lymphoma, Large B-Cell, Diffuse//Lymphoma, Histiocytic//Histiocytic Lymphomas//Lymphoma, Large Lymphoid, Diffuse//Lymphoma, Histiocytic, Diffuse//Lymphoma, Large Cell, Diffuse//Lymphoma, Diffuse Large-Cell//Lymphoma, Diffuse Large Cell//Diffuse Large-Cell Lymphoma//Diffuse Large Cell Lymphoma//Diffuse Large-Cell Lymphomas//Diffuse, Large B-Cell, Lymphoma//Histiocytic Lymphoma//Histiocytic Lymphoma, Diffuse//Diffuse Histiocytic Lymphoma//Diffuse Histiocytic Lymphomas//Lymphoma, Diffuse Histiocytic//Large Lymphoid Lymphoma, Diffuse//Large-Cell Lymphoma, Diffuse//Large Cell Lymphoma, Diffuse//Diffuse Large B-Cell Lymphoma//Diffuse Large B Cell Lymphoma//Lymphoma, Large-Cell, Diffuse

 

Disease Association Statistics

Total Associated ncRNA Number:58   
More Information
Causal ncRNA Number:54
Network:
Top Causal ncRNAs:
FIRRE  (Score: 0.985791)
NEAT1  (Score: 0.985791)
SNHG14  (Score: 0.985791)
MALAT1  (Score: 0.985791)
FIRRE  (Score: 0.985791)
NEAT1  (Score: 0.985791)
SNHG14  (Score: 0.985791)
MALAT1  (Score: 0.985791)
circPCBP2  (Score: 0.731059)
circAPC  (Score: 0.731059)
More Information

 

Evidence Support

Strong Evidence:In Vivo Experiment//RNA Pull-Down//Transfection//Immunoblotting//qRT-PCR//Luciferase Report Assay//Cell Proliferation Assay
Weak Evidence:

 

Reference

[1] PubMed ID:33986803
Disease Name:Lymphoma, Large B-Cell, Diffuse
Sample:DLBCL tissues
Dysfunction Pattern:Interaction( miR-28-5p/EGFR/PI3K/AKT Signaling Pathway)
Validated Method:In Vivo Experiment//RNA Pull-Down//Transfection//Immunoblotting//qRT-PCR//Luciferase Report Assay//Cell Proliferation Assay
Description:In this study, we found that TUC338 was remarkably upregulated in DLBCL tissues as compared to matched normal tissues. Further, we found that TUC338 was able to directly bind to miR-28-5p and increased EGFR level, resulting in activating carcinogenic PI3K/AKT signaling, thereby facilitating DLBCL uncontrolled growth.
Causality:Yes
Causal Description:Stable knockdown of TUC338 evidently inhibited cell proliferation and chemotherapy resistance to Adriamycin and induced apoptosis.
Clinical-realted Application:High TUC338 was closely related to advanced Ann Arbor stage, resistance to CHOP-like treatment, and high IPI (International Prognostic Index).